ArticleProceedings of the National Academy of Sciences of the United States of America2008
Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Pediatric NIH Workshop: Session I: Nonhuman Primate Models in HIV Prevention Research-A Historical and Comparative Perspective.Journal of medical primatology · 2026Review
- Antiviral Activity and Mucosal Safety of Novel Human-Milk-Inspired Antimicrobial Peptides.Pharmaceutics · 2026Article
- Article
- Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41.Viruses · 2019Review
- Gene-silencing suppressors for high-level production of the HIV-1 entry inhibitor griffithsin inProcess biochemistry (Barking, London, England) · 2018Article
- A scalable low-cost cGMP process for clinical grade production of the HIV inhibitor 5P12-RANTES in Pichia pastoris.Protein expression and purification · 2016Article
- C5A Protects Macaques from Vaginal Simian-Human Immunodeficiency Virus Challenge.Antimicrobial agents and chemotherapy · 2016Article
- A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge.Science translational medicine · 2015Article
- Animal models for microbicide safety and efficacy testing.Current opinion in HIV and AIDS · 2013Review
- Mucosal immunology of HIV infection.Immunological reviews · 2013Review
- Past, present and future molecular diagnosis and characterization of human immunodeficiency virus infections.Emerging microbes & infections · 2012Review
- Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide.Antimicrobial agents and chemotherapy · 2012Article
- Microbicides: topical prevention against HIV.Cold Spring Harbor perspectives in medicine · 2012Review
- Non-specific microbicide product development: then and now.Current HIV research · 2012Review
- Animal models for microbicide studies.Current HIV research · 2012Review
- Clinical use of CCR5 inhibitors in HIV and beyond.Journal of translational medicine · 2011Review
- An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques.PloS one · 2011Article
- Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor.The Journal of infectious diseases · 2010Article
- Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides.The Journal of biological chemistry · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
We have assessed the potential of the fusion inhibitory peptide T-1249 for development as a vaginal microbicide to prevent HIV-1 sexual transmission. When formulated as a simple gel, T-1249 provided dose-dependent protection to macaques against high-dose challenge with three different SHIVs that used either CCR5 or CXCR4 for infection (the R5 virus SHIV-162P3, the X4 virus SHIV-KU1 and the R5X4 virus SHIV-89.6P), and it also protected against SIVmac251 (R5). Protection of half of the test animals was estimated by interpolation to occur at T-1249 concentrations of approximately 40-130 muM, whereas complete protection was observed at 0.1-2 mM. In vitro, T-1249 had substantial breadth of activity against HIV-1 strains from multiple genetic subtypes and in a coreceptor-independent manner. Thus, at 1 muM in a peripheral blood mononuclear cell-based replication assay, T-1249 inhibited all 29 R5 viruses, all 12 X4 viruses and all 7 R5X4 viruses in the test panel, irrespective of their genetic subtype. Combining lower concentrations of T-1249 with other entry inhibitors (CMPD-167, BMS-C, or AMD3465) increased the proportion of test viruses that could be blocked. In the PhenoSense assay, T-1249 was active against 636 different HIV-1 Env-pseudotyped viruses of varying tropism and derived from clinical samples, with IC(50) values typically clustered in a 10-fold range approximately 10 nM. Overall, these results support the concept of using T-1249 as a component of an entry inhibitor-based combination microbicide to prevent the sexual transmission of diverse HIV-1 variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.